Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DAWN - Day One Biopharmaceuticals, Inc.

IEX Last Trade
12.98
0.120   0.924%

Share volume: 35,187
Last Updated: Thu 26 Dec 2024 08:30:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$12.86
0.12
0.93%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.16%
1 Month
-6.43%
3 Months
-11.34%
6 Months
-5.73%
1 Year
-17.57%
2 Year
-34.49%
Key data
Stock price
$12.98
P/E Ratio 
0.00
DAY RANGE
$12.47 - $12.92
EPS 
$0.00
52 WEEK RANGE
$12.47 - $18.07
52 WEEK CHANGE
-$15.48
MARKET CAP 
1.215 B
YIELD 
N/A
SHARES OUTSTANDING 
87.760 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,024,900
AVERAGE 30 VOLUME 
$980,360
Company detail
CEO: Jeremy Bender
Region: US
Website: dayonebio.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Day One Biopharmaceuticals, Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor.

Recent news